Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Deals

Luye Life Sciences Partners with Uzbekistan to Establish Vaccine Center

Fineline Cube Sep 15, 2022

China-based Luye Life Sciences Group has struck a partnership with the Ministry of Innovation and...

Company Deals

Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion

Fineline Cube Sep 15, 2022

Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...

Company Drug

Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance

Fineline Cube Sep 15, 2022

China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized...

Company Deals

Bide Pharmatech Set for IPO on Shanghai’s STAR Market

Fineline Cube Sep 15, 2022

Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make...

Drug Policy / Regulatory

NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Sep 15, 2022

The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for...

Company Drug

Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment

Fineline Cube Sep 15, 2022

Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...

Policy / Regulatory

Guangdong Launches Free HPV Vaccination Program for School-aged Girls

Fineline Cube Sep 15, 2022

Guangdong province has rolled out a free HPV vaccination program this month, aimed at improving...

Company Drug

Suzhou Zelgen Completes Phase II Study of Jakinib for Ankylosing Spondylitis

Fineline Cube Sep 15, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a multi-center, randomized...

Policy / Regulatory

Hubei Province Proposes National TCM Patent Medicine Procurement Alliance

Fineline Cube Sep 15, 2022

The Healthcare Security Administration of Hubei Province has proposed the establishment of a national traditional...

Company Drug

Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study

Fineline Cube Sep 15, 2022

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced that it has received approval from...

Company Drug

CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment

Fineline Cube Sep 15, 2022

The Center for Drug Evaluation (CDE) website indicates that Beijing Pearl Biotechnology Co., Ltd’s APL-101/PLB1001...

Company Drug

Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study

Fineline Cube Sep 15, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...

Company Drug

I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial

Fineline Cube Sep 14, 2022

China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...

Company Drug

Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals

Fineline Cube Sep 14, 2022

The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO:...

Company Drug

Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod

Fineline Cube Sep 14, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...

Company Deals

Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital

Fineline Cube Sep 14, 2022

China-based single-use bronchoscope specialist Hunan Vathin Medical Instrument Co., Ltd reportedly raised “hundreds of millions”...

Company Policy / Regulatory

NMPA Issues Guidelines on Medical Device Grading Administration

Fineline Cube Sep 14, 2022

The National Medical Products Administration (NMPA) has released a set of Guiding Opinions on “Medical...

Policy / Regulatory

Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review

Fineline Cube Sep 14, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced that a registrational clinical filing for its FB2001...

Company Drug

Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study

Fineline Cube Sep 14, 2022

China-based Luye Pharma Group (HKG: 2186) announced that it has received approval from the US...

Company Deals

Hengrui Medicine to Incentivize Employees with Share Distribution

Fineline Cube Sep 14, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced plans to incentivize its employees...

Posts pagination

1 … 649 650 651 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.